This company represents an outstanding investment opportunity, bringing groundbreaking AI-driven diagnostics to address critical gaps in healthcare. With a unique yeast-based platform that delivers rapid, cost-effective tests for metabolic disorders, chronic pain, and toxicology, it’s positioned to lead an under-served yet expanding market.
The diagnostic solutions it offers are designed to minimize regulatory burdens, reduce healthcare costs, and provide scalable testing options for high-demand areas like drug impairment and pain management. Already at the MVP stage with early partnerships, the company is primed for growth. Raising $5M to accelerate commercialization, expand its assay portfolio, and deepen partnerships, this venture offers investors a rare chance to enter at a pivotal phase in a high-impact, multi-billion dollar industry.
Let us know, if you'd like to request more information about the company, or if you'd like to hear a great pitch first.
Contact Us